The Clinical Spectrum of PTEN Mutations

Area of Science:

• Genetics and Molecular Biology
• Oncology
• Developmental Biology

Background:

• The PTEN gene acts as a tumor suppressor, regulating the PI3K/AKT/mTOR pathway.
• PTEN dysfunction leads to dysregulated growth and is linked to Cowden syndrome, a hereditary cancer predisposition disorder.
• Germline PTEN mutations manifest in a wide spectrum of clinical features, encompassing cancer and neurodevelopmental disorders.

Purpose of the Study:

• To elucidate the relationship between germline PTEN mutations and the diverse clinical manifestations of PTEN hamartoma tumor syndrome (PHTS).
• To highlight the importance of timely diagnosis and understanding the natural history of PHTS for effective management.
• To emphasize the need for gene-informed care, including cancer surveillance and addressing neurodevelopmental concerns.

Main Methods:

• Review of existing literature and clinical data on PTEN mutations and associated syndromes.
• Genetic analysis of individuals with suspected PTEN-related disorders.
• Phenotypic characterization and correlation with specific PTEN mutations.

Main Results:

• Germline PTEN mutations are the underlying cause of a broad phenotypic spectrum, now recognized under the umbrella term PTEN hamartoma tumor syndrome (PHTS).
• PHTS encompasses seemingly disparate conditions, ranging from hereditary cancer predisposition to autism spectrum disorder.
• The study reinforces the link between PTEN dysfunction and overgrowth conditions.

Conclusions:

• PTEN hamartoma tumor syndrome (PHTS) is a clinically significant condition resulting from germline PTEN mutations.
• Early identification of PHTS is essential for implementing appropriate cancer surveillance protocols and managing neurodevelopmental symptoms.
• Understanding the natural history of PHTS facilitates personalized, gene-informed medical management.